Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 18/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 18/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 17/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 17/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 17/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 17/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 17/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 17/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 17/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2564969 | 0.86 | HDAC3 (0.66) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL2569160 | 0.86 | HDAC1 (0.78) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL2569377 | 0.84 | HDAC1 (0.71) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL2560979 | 0.83 | HDAC3 (0.58) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL2566675 | 0.82 | HDAC1 (0.88) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL2568829 | 0.81 | HDAC3 (0.71) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL2571106 | 0.80 | HDAC3 (0.65) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL2568713 | 0.80 | HDAC3 (0.58) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL2565161 | 0.79 | HDAC3 (0.66) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL2567973 | 0.79 | HDAC1 (0.79) | HDAC1HDAC6HDAC3HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1626961-B1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RES INST OF BIOSCIENCE (KR) | 2011-11-02 | — | — | EP | claimed |
| US-7846963-B2 | 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-12-07 | — | — | US | claimed |
| CN-100534984-C | Novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RES INST OF BIOSCIENCE (KR) | 2009-09-02 | — | — | CN | claimed |
| CN-100467021-C | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RES INST OF BIOSCIENCE (KR) | 2009-03-11 | — | — | CN | claimed |
| EP-1626961-A4 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RES INST OF BIOSCIENCE (KR) | 2008-07-16 | — | — | EP | claimed |
| US-20070167486-A1 | Novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-07-19 | — | — | US | claimed |
| JP-2007501855-A | — | — | 2007-02-01 | — | — | JP | claimed |
| CN-1822832-A | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RES INST OF BIOSCIENCE (KR) | 2006-08-23 | — | — | CN | claimed |
| US-20060173043-A1 | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2006-08-03 | — | — | US | claimed |
| CN-1791579-A | Novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RES INST OF BIOSCIENCE (KR) | 2006-06-21 | — | — | CN | claimed |
| EP-1626961-A1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2006-02-22 | — | — | EP | claimed |
| WO-2004101523-A1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2004-11-25 | — | — | WO | claimed |
| EP-1626961-B1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RES INST OF BIOSCIENCE (KR) | 2011-11-02 | — | — | EP | disclosed |
| US-7846963-B2 | 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-12-07 | — | — | US | disclosed |
| US-7846963-B2 | 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-12-07 | — | — | US | disclosed |
| US-7846963-B2 | 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-12-07 | — | — | US | disclosed |
| EP-1663201-A1 | A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2006-06-07 | — | — | EP | disclosed |
| EP-1626961-A1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2006-02-22 | — | — | EP | disclosed |
| WO-2005004861-A1 | A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004101523-A1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167486-A1 | Novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | NOD2, NOD1, BMP2 | HDAC1 215/4885HDAC6 247/4885HDAC3 489/4885 |
| US-20060173043-A1 | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | MALT1, BRCA1, MCL1 | HDAC1 2103/4885HDAC6 2337/4885HDAC3 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.